ABSTRACT: This is a SWATH proteomic survey of ~330 BXD cohorts, including some biological and technical injection replicates, across an aging time course, with individuals from ~6 to ~24 months of age.
Project description:The objective of this research is to identify differentially expressed genes (DEGs) in AGS and SUN cell samples treated with BXD-0 (0 mg/mL), BXD-L (0.5 mg/mL), and BXD-M (1 mg/mL) (n=3 per group). DEGs were analyzed both between treatment groups (e.g., BXD-L vs. BXD-0) and between cell lines (AGS vs. SUN).
Project description:This SuperSeries is composed of the following subset Series: GSE20425: Hepatic gene expression during liver regeneration in response to partial hepatectomy: early time points (0.5h,1h,2h,4h) GSE20426: Hepatic gene expression during liver regeneration in response to partial hepatectomy: late time points (24h, 38h, 48h) Refer to individual Series
Project description:Colitis-associated colorectal cancer (CAC), a subtype of colorectal cancer arising from chronic colonic inflammation, remains without specific therapeutic agents. Banxia-Xiexin decoction (BXD), a traditional Chinese medicine, is clinically used to treat gastritis and ulcerative colitis; however, its efficacy in CAC and associated mechanisms are not well understood. This study aimed to evaluate the therapeutic potential of BXD against CAC and explore its molecular mechanisms. A CAC mouse model was induced using azoxymethane/dextran sulfate sodium (AOM/DSS), and BXD was administered at vary-ing doses (0.95, 1.9, or 3.8 g/kg/day), alongside a sulfasalazine control. Therapeutic effica-cy was assessed by analyzing disease activity index, inflammatory markers, and histo-pathological changes. Additionally, 4D label-free proteomics and serum metabolomics were conducted to elucidate potential mechanisms. BXD significantly improved disease outcomes in CAC mice by reducing colonic inflammation and tumor hyperplasia, while lowering serum levels of TNF-α, IL-6, IL-1β, and IFN-γ. Metabolomic profiling suggested that BXD modulates valine, leucine, and isoleucine metabolism. Proteomic analysis re-vealed differentially expressed proteins (DEPs) enriched in complement and coagulation cascade pathways. Key DEPs (Fgg, Fgb, C3, and Cfh) were reversed by BXD treatment, which was confirmed at the mRNA level by qRT-PCR. In conclusion, BXD exerts protec-tive effects against CAC by regulating inflammatory responses and modulating amino acid metabolism and complement pathways. These findings provide novel insights into the pharmacological basis of BXD and support its potential clinical application in CAC therapy.
Project description:The process of liver regeneration can be divided into a series of stages that include initial inductive or priming events through cellular mitosis. Following two-thirds liver resection, the liver undergoes the “priming” phase, in which cytokines TNF-a and IL-6 activate their respective receptors in hepatocytes. This leads to the activation of several key transcription factors: NF-kB, AP-1, Stat 3, Stat 1, and C/EBP-b and -d . These transcription factors induce the expression of immediate early genes. HGF is also expressed at this time and involved in the transition of quiescent hepatocytes into the G1 phase of the cell cycle. During the G1 phase, delayed early genes are expressed followed by induction of cell cycle–related genes, both of which require new protein synthesis for their production. Increased expression of FoxM1B and TGF-a occurs at the G1/S transition and is correlated with increased expression of cyclinD1 and decreased expression of cdk inhibitors. During the G2/M phase of the cell cycle, FoxM1B directly elevates cyclinB1, cyclinB2, and cdc25B expression. Additionally, FoxM1B is associated with increased cyclinF and p55cdc, which are involved in completion of the cell cycle following partial hepatectomy. In mice, two-thirds partial hepatectomy promotes proliferation of liver cells and rapid growth of the remaining liver tissue, resulting in complete restoration of organ mass in approximately 7 days (Mackey S. et al. Hepatology 2003 Dec;38(6):1349-52). Liver tissue was collected 0h, 24h, 38h, and 48h after partial hepatectomy or sham surgery from both young (5-6 months) and old (25-27 months) CB6F1 mice. All control and partial hepatectomy samples were assayed in triplicate. Relative gene expression levels were determined using Affymetrix moe430_2 oligo arrays.
Project description:Transcript data from livers from fasted-state BXD strains on chow or high fat diet We used microarrays to compare the hepatic expression differences across the BXD strain family and across two diverse diets
Project description:Transcript data from heart tissue from fasted-state male BXD strains on chow or high fat diet We used microarrays to compare the heart expression differences across the BXD strain family and across two diverse diets
Project description:Transcript data from brown adipose tissue from fasted-state male BXD strains on chow or high fat diet We used microarrays to compare the brown adipose expression differences across males from the BXD strain family and across two diverse diets
Project description:Transcript data from quadriceps skeletal muscle from fasted-state male BXD strains on Quadriceps, Chow or Quadriceps, High fat diet We used microarrays to compare the skeletal muscle expression differences across males in the BXD strain family and across two diverse diets
Project description:Transcript data from subcutaneous white adipose tissue (scWAT) from fasted-state male BXD strains on chow or high fat diet We used microarrays to compare the subcutaneous white adipose tissue (scWAT) expression differences across the BXD strain family and across two diverse diets